| Germany – Data analysis services – Gesundheitsberichterstattung | Data analysis services | - | 7 août 2026 | 8 juil. 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta | Pharmaceutical products | - | 30 août 2028 | 8 juil. 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-07 - Follitropin delta | Pharmaceutical products | - | 30 août 2026 | 8 juil. 2026 | Actif |
| Germany – IT services: consulting, software development, Internet and support – Fotorealistischer Beratungsavatar | IT services: consulting | - | 14 juil. 2026 | 8 juil. 2026 | Actif |
| Germany – Software package and information systems – eProcurement Plattform | Software package and information systems, Procurement software package, +4 | - | 31 juil. 2026 | 7 juil. 2026 | Actif |
| Germany – IT services: consulting, software development, Internet and support – Unterstützungsleistungen ePA App Accord-cadre | IT services: consulting | - | 20 juil. 2026 | 1 juil. 2026 | Actif |
| Germany – Telephone and data transmission services – SMS/mTan-Dienstleister 2026 | Telephone and data transmission services, Mobile-telephone services, +1 | - | 3 août 2026 | 1 juil. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-08 Accord-cadre | Pharmaceutical products | - | 30 juil. 2028 | 1 juil. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-05 Alectinib | Pharmaceutical products | - | 30 juil. 2028 | 1 juil. 2026 | Actif |
| Germany – IT services: consulting, software development, Internet and support – Aufbau Apache Kafka-Plattform Accord-cadre | IT services: consulting, Software package and information systems | - | 22 juil. 2026 | 24 juin 2026 | Actif |
| Germany – Advertising and marketing services – Gestaltung von Print- und Nonprintmedien Accord-cadre | Advertising and marketing services | - | 16 juil. 2026 | 24 juin 2026 | Actif |
| Germany – IT services: consulting, software development, Internet and support – Servicevertrag Workplace Dienstleistungen 2026 Accord-cadre | IT services: consulting, Repair, +3 | - | 15 juil. 2026 | 23 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab | Pharmaceutical products | - | 30 juil. 2028 | 17 juin 2026 | Actif |
| Germany – Mail transport by road – Briefdienstleistungen XII Accord-cadre | Mail transport by road, Mail delivery services | - | 13 juil. 2026 | 16 juin 2026 | Actif |
| Germany – IT services: consulting, software development, Internet and support – Fotorealistischer Beratungsavatar | IT services: consulting | - | 13 juil. 2026 | 15 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-10 | Pharmaceutical products | - | 30 juil. 2028 | 15 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-07 Accord-cadre | Pharmaceutical products | - | 29 juin 2028 | 14 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-12 | Pharmaceutical products | - | 29 juin 2028 | 14 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-25 - Follitropin alfa | Pharmaceutical products | - | 30 juil. 2028 | 7 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-32 - Golimumab | Pharmaceutical products | - | 30 juil. 2026 | 7 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-21 - Golimumab | Pharmaceutical products | - | 30 juil. 2027 | 7 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-22 - Ustekinumab | Pharmaceutical products | - | 30 juil. 2027 | 7 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-24 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml) | Pharmaceutical products | - | 30 juil. 2027 | 4 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-25 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml) | Pharmaceutical products | - | 29 nov. 2026 | 4 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-23 - Darbepoetin alfa | Pharmaceutical products | - | 30 juil. 2028 | 4 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-09 - Teduglutid | Pharmaceutical products | - | 29 juin 2028 | 1 juin 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 20 - Peginterferon beta 1a | Pharmaceutical products | - | 30 juil. 2028 | 31 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 19 - Denosumab (Wirkstärke 60mg) | Pharmaceutical products | - | 29 nov. 2027 | 25 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-31 - Denosumab | Pharmaceutical products | - | 29 nov. 2027 | 25 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab | Pharmaceutical products | - | 30 oct. 2027 | 20 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 18 Omalizumab | Pharmaceutical products | - | 30 juin 2028 | 20 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-04 Cariprazin | Pharmaceutical products | - | 30 juin 2028 | 20 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 14 - Lipegfilgrastim | Pharmaceutical products | - | 29 juin 2028 | 19 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 17 Interferon beta-1b (Fertigarzneimittel: Betaferon(R)) | Pharmaceutical products | - | 30 juin 2028 | 19 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 16 Epoetin theta | Pharmaceutical products | - | 30 juin 2028 | 18 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 15 Ranibizumab | Pharmaceutical products | - | 30 juin 2027 | 18 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta | Pharmaceutical products | - | 30 juin 2028 | 7 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-13 - Romiplostim | Pharmaceutical products | - | 29 juin 2028 | 7 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-08 | Pharmaceutical products | - | 29 juin 2028 | 7 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-01 | Pharmaceutical products | - | 27 févr. 2027 | 4 mai 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-03 - Dolutegravir/Rilpivirin (Wirkstoffkombination) | Pharmaceutical products | - | 31 mai 2028 | 23 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-30 - Lenograstim | Pharmaceutical products | - | 30 déc. 2027 | 23 avr. 2026 | Actif |
| Germany – Surgical hospital services – Roboter-assistierte Chirurgie und Fast-track-Verfahren bei Darmerkrankungen | Surgical hospital services, Medical hospital services | - | 30 avr. 2050 | 21 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-11 - Infliximab (Darreichungsform zur intravenösen Anwendung) | Pharmaceutical products | - | 30 mai 2028 | 19 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | 30 mai 2028 | 19 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-05 | Pharmaceutical products | - | 30 mai 2027 | 15 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-07 | Pharmaceutical products | - | 30 mai 2028 | 14 avr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-06 - Safinamid | Pharmaceutical products | - | 29 avr. 2027 | 26 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-09 - Etanercept | Pharmaceutical products | - | 29 avr. 2028 | 22 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim | Pharmaceutical products | - | 29 avr. 2028 | 18 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-07 - Tocilizumab | Pharmaceutical products | - | 30 avr. 2028 | 18 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-04 - Natalizumab i.v. | Pharmaceutical products | - | 29 avr. 2028 | 18 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-08 - Filgrastim | Pharmaceutical products | - | 30 avr. 2028 | 18 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-05 | Pharmaceutical products | - | 29 avr. 2028 | 17 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-02 - Ponatinib | Pharmaceutical products | - | 29 avr. 2028 | 15 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-06 - Teriparatid | Pharmaceutical products | - | 29 avr. 2028 | 15 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-06 | Pharmaceutical products | - | 30 mars 2028 | 5 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-02 | Pharmaceutical products | - | 30 mars 2028 | 5 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-04 - Tramadol/Dexketoprofen | Pharmaceutical products | - | 30 mars 2028 | 2 mars 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD) | Pharmaceutical products | - | 30 août 2027 | 24 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD) | Pharmaceutical products | - | 30 août 2027 | 24 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-03 | Pharmaceutical products | - | 30 mars 2028 | 17 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-10 | Pharmaceutical products | - | 29 sept. 2027 | 16 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-02 | Pharmaceutical products | - | 30 mars 2027 | 16 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-01 - Cannabis | Pharmaceutical products | - | 30 mars 2028 | 16 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-10 | Pharmaceutical products | - | 29 sept. 2026 | 15 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-02 - Interferon beta 1a (Fertigarzneimittel: Rebif (R)) | Pharmaceutical products | - | 30 mars 2028 | 9 févr. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid | Pharmaceutical products | - | 28 févr. 2028 | 27 janv. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-02 - Lanreotid | Pharmaceutical products | - | 28 févr. 2028 | 21 janv. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-11 | Pharmaceutical products | - | 30 oct. 2026 | 18 janv. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-01 | Pharmaceutical products | - | 28 févr. 2028 | 18 janv. 2026 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-08 | Pharmaceutical products | - | 30 août 2027 | 14 déc. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-16 | Pharmaceutical products | - | 30 janv. 2028 | 14 déc. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-07 | Pharmaceutical products | - | 30 juil. 2027 | 14 déc. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-38 - PEG-Epoetin beta | Pharmaceutical products | - | 30 janv. 2028 | 3 déc. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta | Pharmaceutical products | - | 30 janv. 2028 | 3 déc. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | 30 janv. 2028 | 23 nov. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-37 - Peginterferon alfa-2a | Pharmaceutical products | - | 30 janv. 2028 | 23 nov. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-15 | Pharmaceutical products | - | 30 déc. 2027 | 17 nov. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-35 - Baricitinib | Pharmaceutical products | - | 30 déc. 2027 | 13 nov. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-34 - Formoterol/Glycopyrronium/Budesonid (Wirkstoffkombination) | Pharmaceutical products | - | 29 nov. 2027 | 27 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-13 | Pharmaceutical products | - | 30 déc. 2027 | 22 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-33 - Propranolol (Darreichungsform: Lösung zum Einnehmen) | Pharmaceutical products | - | 30 déc. 2027 | 19 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-28 - Abatacept | Pharmaceutical products | - | 29 nov. 2027 | 14 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-31 - Doravirin | Pharmaceutical products | - | 29 nov. 2027 | 12 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination) | Pharmaceutical products | - | 29 nov. 2027 | 12 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-14 - Guanfacin (RET, Wirkstärken: 1-4 mg) | Pharmaceutical products | - | 30 oct. 2026 | 8 oct. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-30 - Afatinib | Pharmaceutical products | - | 30 oct. 2027 | 24 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-29 - Isavuconazol | Pharmaceutical products | - | 30 oct. 2027 | 22 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-12 | Pharmaceutical products | - | 30 oct. 2027 | 18 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-28 - Abemaciclib | Pharmaceutical products | - | 30 oct. 2027 | 17 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-27 - Ribociclib | Pharmaceutical products | - | 30 oct. 2027 | 17 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-27 - Tocilizumab | Pharmaceutical products | - | 30 oct. 2026 | 14 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro (ATC: A10AB04, Wirkstärke: 100 U/ml) | Pharmaceutical products | - | 30 oct. 2027 | 9 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-26 - Ponesimod | Pharmaceutical products | - | 30 oct. 2027 | 8 sept. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-11 - Eltrombopag | Pharmaceutical products | - | 29 sept. 2027 | 25 août 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (Wirkstoffkombination) | Pharmaceutical products | - | 30 oct. 2027 | 21 août 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-24 - Vericiguat | Pharmaceutical products | - | 29 sept. 2027 | 18 août 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid | Pharmaceutical products | - | 29 sept. 2027 | 18 août 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-22 - Triptorelin embonat | Pharmaceutical products | - | 29 sept. 2027 | 7 août 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-09 | Pharmaceutical products | - | 30 août 2027 | 27 juil. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination) | Pharmaceutical products | - | 30 août 2027 | 22 juil. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-23 - Rilpivirin (Darreichungsform: Filmtabletten) | Pharmaceutical products | - | 29 sept. 2027 | 22 juil. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim | Pharmaceutical products | - | 30 août 2027 | 16 juil. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid | Pharmaceutical products | - | 30 août 2027 | 13 juil. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-09 Accord-cadre | Pharmaceutical products | - | 30 août 2026 | 23 juin 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab | Pharmaceutical products | - | 30 juil. 2027 | 12 juin 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-18 - Insulin glargin (Wirkstärke: 100 U/ml) | Pharmaceutical products | - | 30 août 2027 | 9 juin 2025 | Actif |
| Germany – Batteries – Rahmenvertrag Einwegbatterien für Sprachprozessoren von Cochlea-Implantaten | Batteries | - | 31 déc. 2099 | 3 juin 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-17 -Agalsidase beta | Pharmaceutical products | - | 29 juin 2027 | 25 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-16 - Agalsidase alfa | Pharmaceutical products | - | 29 juin 2027 | 25 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-17 - Beclometason, Formoterol, Glycopyrronium (Wirkstoffkombination) ATC: R03AL09 | Pharmaceutical products | - | 29 juin 2027 | 22 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-16 - Empagliflozin | Pharmaceutical products | - | 29 juin 2027 | 22 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-14 | Pharmaceutical products | - | 30 janv. 2027 | 21 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-20 - Metformin/Dapagliflozin (Wirkstoffkombination) | Pharmaceutical products | - | 30 juil. 2027 | 19 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15 | Pharmaceutical products | - | 30 juil. 2027 | 19 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-18 - Glycopyrroniumbromid/Formoterol (Wirkstoffkombination) | Pharmaceutical products | - | 30 juil. 2027 | 11 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-13 - Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination) | Pharmaceutical products | - | 30 juil. 2027 | 11 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-12 - Insulin-isophan (human) | Pharmaceutical products | - | 30 juil. 2027 | 11 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-11 - Insulin, normal (human) | Pharmaceutical products | - | 30 juil. 2027 | 11 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-19 - Tafamidis | Pharmaceutical products | - | 30 mai 2027 | 4 mai 2025 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-09 - Lutropin alfa / Follitropin alfa (Wirkstoffkombination) | Pharmaceutical products | - | 30 mai 2027 | 22 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-10 - Choriongonadotropin alfa | Pharmaceutical products | - | 30 mai 2027 | 22 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-15 - Tacrolimus (Retardtabletten) | Pharmaceutical products | - | 30 mai 2027 | 21 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination) | Pharmaceutical products | - | 30 mai 2027 | 16 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-14 - Tiotropiumbromid/Olodaterol (Wirkstoffkombination) | Pharmaceutical products | - | 30 mai 2027 | 16 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant | Pharmaceutical products | - | 30 mai 2027 | 8 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-13 - Somatropin | Pharmaceutical products | - | 30 déc. 2026 | 1 avr. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-11 - Umeclidiniumbromid | Pharmaceutical products | - | 29 avr. 2027 | 30 mars 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-10 - Umeclidiniumbromid+Vilanterol | Pharmaceutical products | - | 29 avr. 2027 | 27 mars 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-03 - Interferon beta-1a (Fertigarzneimittelbezeichnung: Avonex(R)) | Pharmaceutical products | - | 29 avr. 2027 | 16 mars 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-04 - Follitropin beta | Pharmaceutical products | - | 30 avr. 2027 | 16 mars 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-08 - Roxadustat | Pharmaceutical products | - | 30 mars 2027 | 5 mars 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2025-09 - Cannabis | Pharmaceutical products | - | 30 mars 2027 | 24 févr. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | 27 févr. 2027 | 23 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-04 - Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R)) | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination) | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-01 | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R)) | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-03 - Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)) | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-06 - Dolutegravir | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination) | Pharmaceutical products | - | 27 févr. 2027 | 20 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) | Pharmaceutical products | - | 27 févr. 2027 | 19 janv. 2025 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-13 - Apremilast | Pharmaceutical products | - | 29 déc. 2026 | 19 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-12 - Dornase alfa | Pharmaceutical products | - | 29 déc. 2026 | 17 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten) | Pharmaceutical products | - | 29 déc. 2026 | 17 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-12 - Tofacitinib | Pharmaceutical products | - | 29 déc. 2026 | 17 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-13 | Pharmaceutical products | - | 29 déc. 2026 | 14 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination) | Pharmaceutical products | - | 29 déc. 2026 | 13 nov. 2024 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-10 - Tiotropiumbromid (Spiriva(R) Respimat, ATC: R03BB04) | Pharmaceutical products | - | 28 nov. 2026 | 25 sept. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-11 - Hepatitis-B-Immunglobulin (ATC-Code J06BB04) | Pharmaceutical products | - | 29 oct. 2026 | 22 sept. 2024 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol (Wirkstoffkombination) | Pharmaceutical products | - | 30 sept. 2026 | 30 juil. 2024 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-07 - Dapagliflozin | Pharmaceutical products | - | 29 août 2026 | 19 juil. 2024 | Actif |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-06 - Aclidiniumbromid/Formoterol (Wirkstoffkombination) Accord-cadre | Pharmaceutical products | - | 29 août 2026 | 15 juil. 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-04 - Follitropin alfa Accord-cadre | Pharmaceutical products | - | 29 juil. 2026 | 21 juin 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-06 - Peginterferon beta-1a Accord-cadre | Pharmaceutical products | - | 29 juil. 2026 | 20 juin 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-08 - Darbepoetin alfa Accord-cadre | Pharmaceutical products | - | 29 juil. 2026 | 19 juin 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-05 - Ustekinumab Accord-cadre | Pharmaceutical products | - | 29 juil. 2026 | 17 juin 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-07 - Epoetin zeta Accord-cadre | Pharmaceutical products | - | 29 juil. 2026 | 17 juin 2024 | Actif |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-03 - Everolimus (ATC: L04AH02; TAB) Accord-cadre | Pharmaceutical products | - | 29 oct. 2026 | 15 févr. 2024 | Actif |